Dynavax Technologies Corporation (NASDAQ:DVAX) announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at …
After market close, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that it intends to offer and sell $125.0 million of shares of its common stock, …
Valeant May Post Weak 2Q Print- But Might Not Dent Investor Sentiment After All Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivers its second-quarter print …
Valeant’s Debt Problems Continue to Be Overhangs for the Stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were stumbling almost 6%, having lost practically 13% …
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that the U.S.
Dynavax’s Advantage Weighs Towards Heplisav’s Benefits Dynavax Technologies Corporation (NASDAQ:DVAX) shares are racing 5% today after releasing second-quarter earnings. However, this rocket momentum …
Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the second quarter ended June 30, 2017. Cash, cash equivalents and marketable securities were $127.
William Blair analyst Y Katherine Xu is out with a bullish note on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), after the FDA’s Vaccines and Related Biological …
Dynavax Technologies Corporation (NASDAQ:DVAX) shares are skyrocketing over 70% after the FDA VRBPAC panel voted 12-1 with 3 abstentions that the safety to …
The FDA Vaccines & Related Biological Products Advisory Committee (VRBPAC) is meeting today to discuss the safety and efficacy of Dynavax Technologies Corporation’s (NASDAQ:DVAX) experimental …
